Skip to main content

TURP — Transurethral Resection of the Prostate

Transurethral Resection of the Prostate (TURP) is the historical gold standard surgical treatment for LUTS secondary to BPH and the reference comparator against which every newer surgical and minimally invasive therapy is measured.[1][2][3] Over a century of refinement has produced the most extensive long-term outcome dataset of any BPH procedure. For positioning vs other BPH options see BPH & Male LUTS — chooser.

Mechanism​

An electrosurgical loop is passed through a resectoscope and used to systematically resect obstructing prostatic adenoma in a piecemeal fashion. The loop simultaneously cuts tissue and coagulates blood vessels. Resected chips fall into the bladder and are evacuated at the end of the procedure — providing tissue for histological analysis, with incidental prostate cancer detected in approximately 9.8% of TURP specimens.[4]

Monopolar TURP (M-TURP)​

  • Single active electrode (the loop); current passes through the patient's body to a return pad.
  • Requires non-conductive hypo-osmolar irrigation (glycine, sorbitol, or mannitol) — creating the risk of TUR syndrome (dilutional hyponatremia from fluid absorption).
  • Resection time is limited to ~ 60–90 minutes to minimize fluid-absorption risk.[5][6]

Bipolar TURP (B-TURP)​

  • Bipolar circuit at the resectoscope tip — energy does not traverse the patient.
  • Uses normal saline (0.9% NaCl) as irrigant — virtually eliminates TUR syndrome risk.
  • Allows longer resection times and may reduce thermal damage to surrounding tissues.[5]

Procedure​

Performed under general or spinal / regional anesthesia; typical OR time 30–60 min depending on size.[2][7][6]

  1. 24–28 Fr resectoscope introduced through the urethra under direct vision.
  2. Bladder inspected for stones, diverticula, or tumors.
  3. Identify landmarks: bladder neck (proximal), verumontanum (distal limit of resection), external sphincter.
  4. Systematic resection — typically median lobe first (if present), then lateral lobes, working from bladder neck distally toward verumontanum.
  5. Create a midline trench to allow the lateral lobe to fall backward, then resect remaining adenoma while preserving the thin surgical capsule.
  6. Hemostasis: coagulate arterial bleeders (typically at 1, 5, 7, 11 o'clock).
  7. Tissue chips evacuated using Ellik evacuator.
  8. Three-way Foley placed for continuous bladder irrigation.

Operative parameters (pooled contemporary RCTs)[7]​

  • Mean resection time: 38.5 min
  • Mean resected tissue: 25.8–28.4 g
  • Mean catheterization: 2–2.5 d
  • Mean LOS: 3–5 d (varies by country / practice)

Patient selection​

Based on AUA / EAU guidelines[5][8][3]:

  • Moderate-to-severe LUTS (IPSS ≥ 12) refractory to medical therapy.
  • Prostate volume 30–80 mL (guideline-recommended); can be performed up to ~ 100–150 mL by experienced surgeons, though enucleation or simple prostatectomy is preferred for > 80 mL.[9][5]
  • Absolute indications: refractory urinary retention, recurrent UTIs, bladder stones, gross hematuria, renal insufficiency secondary to BPH.[5]
  • Treats obstructive median lobes.
  • Provides tissue for histological analysis — important for incidental prostate cancer detection.

Clinical efficacy​

TURP delivers among the most robust and durable symptom improvements of any BPH procedure.[3][7][4]

ParameterBaseline12 months60 months
IPSS~ 22–24−15.1−13.2
Qmax (mL/s)~ 10.4+10.6+6.3
PVR (mL)~ 180~ 31—
QoL—69%sustained

A meta-analysis of 20 RCTs confirmed 70% IPSS reduction and 69% QoL improvement with up to 5 yr follow-up.[1] In the Cochrane network meta-analysis, TURP was the reference treatment with the highest likelihood of being most efficacious for urinary symptoms, QoL, and retreatment among all procedures compared.[3]

A prospective study of TURP in prostates 70–150 mL showed larger prostates achieved better IPSS and Qmax improvements than smaller prostates with similar complication rates — prostate size alone is not a contraindication.[9]

Monopolar vs Bipolar — the Cochrane comparison​

The 2019 Cochrane systematic review (59 RCTs, 8,924 participants) provides the definitive head-to-head.[5]

ParameterM-TURPB-TURPSignificance
IPSS / Qmax / QoL / IIEFsimilarsimilarno difference
TUR syndrome18 / 1,0003 / 1,000B-TURP superior (RR 0.17, p < 0.001)
Transfusion29 / 1,00012 / 1,000B-TURP superior (moderate certainty)
Erectile dysfunctionsimilarsimilarno difference
Urinary incontinencesimilarsimilarno difference
Retreatmentsimilarsimilarno difference
Bladder neck stricture0%8.5%M-TURP superior in one RCT[10]

In moderate-to-large prostates specifically, a 7-study meta-analysis confirmed B-TURP had shorter LOS (p = 0.01), shorter catheterization (p = 0.05), and lower TUR syndrome (p = 0.03), with no functional difference at 3 / 6 / 12 months.[11]

Safety profile​

The Bavarian statewide multicenter prospective study (n = 10,654) is the largest contemporary safety dataset.[4]

Perioperative​

  • 30-day mortality 0.10% (improved from historical 0.2–0.4%).[4][12][6]
  • 90-day mortality 1.16% in a Finnish nationwide cohort of 39,320 — though excess mortality attributable to surgery was < 1%.[13]
  • Cumulative short-term morbidity 11.1%.[4]
  • Transfusion 2.9% (contemporary); decreased from 7.1% historically to 0.4% in the most recent era.[4][14]
  • TUR syndrome 1.4% (M-TURP); essentially 0% with bipolar.[4][5]
  • Clot retention 2–5%.[14]
  • UTI 1.7–3.6%.[4][14]
  • Failure to void / AUR 5.8–6.8%.[4][7]
  • Return to OR for bleeding 2.0–5.6%.[4][14]

Late​

  • Urethral stricture 2.2–9.8%.[14]
  • Bladder-neck contracture 0.3–9.2%.[14]
  • Permanent stress urinary incontinence < 1%.[4]

Three-decade temporal trend​

Outcomes have improved substantially across three decades[14]:

OutcomeHistoricalRecent era
Transfusion7.1%0.4%
TUR syndrome1.1%0.0%
Clot retention5%2%
UTI8.2%1.7%
Mortality0.25%0–0.1%

Sexual function​

Sexual dysfunction is TURP's most significant quality-of-life trade-off.

  • Retrograde ejaculation 60–75% — the most common sexual side effect.[3][15] Muntener 2007 prospective n = 1,014 confirmed ejaculatory function score worsened significantly (p < 0.001).[15]
  • Erectile dysfunction 10–14% in most series.[3][15] However, the Muntener 1,014-patient series found erectile function scores did not significantly change post-TURP (p = 0.11), with 3 of 4 patients remaining sexually active.[15]
  • EEP vs TURP (Liu 2020 meta) — EEP may produce more durable preservation of erectile function at long-term follow-up (≥ 48 mo), with slightly higher IIEF-5 scores.[16]

Mechanism of dysfunction[17]​

  • Retrograde ejaculation — destruction of the bladder-neck mechanism during resection.
  • Erectile dysfunction — potential thermal or mechanical injury to the neurovascular bundles via posterolateral capsular perforation.
  • B-TURP theoretically reduces thermal damage but Cochrane meta does not show significantly different sexual outcomes.[5]

Retreatment and durability​

SourcenFollow-upRetreatment rate
He 2023 SR (cumulative)[18]130,1061 / 2 / 3 / 5 yr4.0% / 5.0% / 6.0% / 7.7%
Eredics 2018 Austrian nationwide[12]20,3888 yr8.3% re-TURP; 12.7% all endourological
Frendl 2021 NY claims real-world[19]15,9827 yr15.3% (failure = reoperation + AUR)
Nackeeran 2025 VA nationwide post-2001[20]35,8175 yr15.4% (new procedure within 5 yr); post-2001 OR 1.49 vs pre-2001
Wei 2025 JAMA review[3]—24 / 60 mo5% / 7.7%
Reich 2008 Bavarian early[4]10,654early5.6% surgical revision

Nackeeran 2025 found post-2001 TURP had 49% higher odds of retreatment vs pre-2001 (OR 1.49, p < 0.001) — potentially reflecting reduced trainee exposure as medical therapy and MISTs have become more prevalent.[20]

TURP vs other BPH procedures​

ParameterTURPAEEPAquablationGreenLight PVPUroLiftRezūm
Volume≤ 80 mLAny30–150+ mL≤ 80 mL≤ 80 mL30–80 mL
IPSS Δ 12 mo−15.1−12 to −14−15.1−14.3−11.1−11.3
Qmax Δ 12 mo+10.6+14.0+10.3+12.1+4.0+5.6
5-yr retreatment7.7%1–6.6%~ 4%7.1% (≤ 80 mL)~ 22% (real-world)4.4%
Retrograde ejaculation60–75%78–92%7–10%~ 70% standard / 15–20% hood-sparing0%0–3%
Erectile dysfunction14%5–10%0%0–20%0%0–3%
Tissue for pathologyYesYesYesNoNoNo
AnesthesiaGeneral / spinalGeneral / spinalGeneral / regionalGeneral / spinalLocal / sedationLocal / sedation

TURP has historically been considered a technically demanding procedure requiring significant experience to master. A pooled analysis of contemporary RCTs showed mean resection time 38.5 min with resection efficiency improving over decades.[7]

Concerning training-volume signal:

  • Nackeeran 2025 VA analysis: post-2001 TURP had 49% higher odds of retreatment vs pre-2001 — likely reflecting reduced trainee exposure as medical therapy and MISTs have become more prevalent.[20]
  • TURP remains the 10th most common operation in the UK NHS, with ~ 25,000 prostate operations annually (~ 80% TURP).[21]
  • Learning curve is generally considered 50–100 supervised cases for proficiency.

Where TURP fits in 2026​

Distinguishing strengths​

  • Proven efficacy — 70% IPSS reduction, robust Qmax improvement, durable 5–10 yr outcomes; Cochrane NMA reference treatment.
  • Tissue for histology — incidental prostate cancer in ~ 10% of cases.
  • Universal availability — no specialized equipment beyond a standard resectoscope.
  • Treats median lobes — effective across all anatomical configurations.
  • Well-understood complication profile with declining morbidity and mortality across three decades.

Principal limitations​

  • High retrograde ejaculation rate (60–75%) — substantially worse than Aquablation (7–10%), Rezūm (0–3%), iTIND (~ 1%), UroLift (0%).
  • Size limitation (≤ 80 mL guideline-recommended) — though feasible up to ~ 150 mL by experienced surgeons; AEEP is the more durable option for very large glands.
  • Hospital LOS 3–5 days vs office-based MISTs and outpatient PVP / Aquablation.
  • Possible decline in trainee proficiency in the era of medical therapy and MISTs.[20]

The trend in BPH surgery is toward enucleation (AEEP) for large prostates and MISTs for sexual-function-preservation priority, but TURP remains the most commonly performed procedure and the benchmark against which all others are measured.

See also​

BPH & Male LUTS — chooser · AEEP (HoLEP / ThuLEP / ThuFLEP / BipolEP) · Simple Prostatectomy · Aquablation · GreenLight PVP · UroLift · Rezūm · iTIND · Optilume BPH · PAE

References​

1. Arnold MJ, Gaillardetz A, Ohiokpehai J. Benign prostatic hyperplasia: rapid evidence review. Am Fam Physician. 2023;107(6):613-622.

2. Agrawal MS, Mishra DK. Transurethral resection of prostate. J Endourol. 2022;36(S2):S29-S34. doi:10.1089/end.2022.0305

3. Wei JT, Dauw CA, Brodsky CN. Lower urinary tract symptoms in men. JAMA. 2025;334(9):809-821. doi:10.1001/jama.2025.7045

4. Reich O, Gratzke C, Bachmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180(1):246-249. doi:10.1016/j.juro.2008.03.058

5. Alexander CE, Scullion MM, Omar MI, et al. Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst Rev. 2019;12:CD009629. doi:10.1002/14651858.CD009629.pub4

6. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet. 2003;361(9366):1359-1367. doi:10.1016/S0140-6736(03)13073-5

7. Mayer EK, Kroeze SG, Chopra S, Bottle A, Patel A. Examining the 'gold standard': a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes. BJU Int. 2012;110(11):1595-1601. doi:10.1111/j.1464-410X.2012.11119.x

8. Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2024;211(1):11-19. doi:10.1097/JU.0000000000003698

9. Muzzonigro G, Milanese G, Minardi D, et al. Safety and efficacy of transurethral resection of prostate glands up to 150 mL: a prospective comparative study with 1 year of followup. J Urol. 2004;172(2):611-615. doi:10.1097/01.ju.0000131258.36966.d1

10. Stucki P, Marini L, Mattei A, et al. Bipolar versus monopolar transurethral resection of the prostate: a prospective randomized trial focusing on bleeding complications. J Urol. 2015;193(4):1371-1375. doi:10.1016/j.juro.2014.08.137

11. Bruce A, Krishan A, Sadiq S, Ehsanullah SA, Khashaba S. Safety and efficacy of bipolar transurethral resection of the prostate vs monopolar transurethral resection of prostate in the treatment of moderate-large volume prostatic hyperplasia: a systematic review and meta-analysis. J Endourol. 2021;35(5):663-673. doi:10.1089/end.2020.0840

12. Eredics K, Wachabauer D, Röthlin F, Madersbacher S, Schauer I. Reoperation rates and mortality after transurethral and open prostatectomy in a long-term nationwide analysis: have we improved over a decade? Urology. 2018;118:152-157. doi:10.1016/j.urology.2018.04.032

13. Salmivalli A, Ettala O, Boström PJ, Kytö V. Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study. World J Urol. 2022;40(7):1785-1791. doi:10.1007/s00345-022-03999-0

14. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP) — incidence, management, and prevention. Eur Urol. 2006;50(5):969-979. doi:10.1016/j.eururo.2005.12.042

15. Muntener M, Aellig S, Kuettel R, et al. Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicentre assessment of outcome. Eur Urol. 2007;52(2):510-515. doi:10.1016/j.eururo.2007.01.088

16. Liu Y, Cheng Y, Zhuo L, et al. Impact on sexual function of endoscopic enucleation vs transurethral resection of the prostate for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis. J Endourol. 2020;34(10):1064-1074. doi:10.1089/end.2020.0141

17. Mykoniatis I, Renterghem KV, Sokolakis I. How can we preserve sexual function after ablative surgery for benign prostatic hyperplasia? Curr Drug Targets. 2021;22(1):4-13. doi:10.2174/1389450121666200925143916

18. He W, Ding T, Niu Z, et al. Reoperation after surgical treatment for benign prostatic hyperplasia: a systematic review. Front Endocrinol. 2023;14:1287212. doi:10.3389/fendo.2023.1287212

19. Frendl DM, Chen YW, Chang DC, Kim MM. A claims-based assessment of reoperation and acute urinary retention after ambulatory transurethral surgery for benign prostatic hyperplasia. J Urol. 2021;205(2):532-538. doi:10.1097/JU.0000000000001390

20. Nackeeran S, Morgan KM, Chen H, et al. The 21st century marks a rise in TURP retreatment rates: an analysis of Veterans Health Administration data. World J Urol. 2025;43(1):701. doi:10.1007/s00345-025-06083-5

21. Hashim H, Worthington J, Abrams P, et al. Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial. Lancet. 2020;396(10243):50-61. doi:10.1016/S0140-6736(20)30537-7